Galectin Therapeutics Inc (GALT) CMO reports share sale in Form 4 filing

Rhea-AI Filing Summary

Galectin Therapeutics Inc Chief Medical Officer Jamil Khurram reported vesting and sales of company common stock. On January 2, 2026, 60,000 shares of common stock were acquired at $0 upon vesting of previously granted restricted stock units, then 13,055 of those shares were sold at a weighted average price of $4.1968. Additional sales of 25,499 shares at a weighted average price of $3.8985 on January 5, 2026, and 21,446 shares at a weighted average price of $3.6466 on January 6, 2026, reduced his reported holdings to zero shares. The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025.

Insider Trade Summary

Net Seller: 60,000 shares ($232,402)

Net Sell 5 txns

Insider Jamil Khurram

Role Chief Medical Officer

Sold 60,000 shs ($232K)

Type	Security	Shares	Price	Value
Sale	Common Stock	21,446	$3.6466	$78K
Sale	Common stock	25,499	$3.8985	$99K
Exercise	Common Stock	60,000	$0.00	--
Sale	Common Stock	13,055	$4.1968	$55K
Exercise	Restricted Stock Unit	60,000	$0.00	--

Holdings After Transaction: Common Stock — 0 shares (Direct); Common stock — 21,446 shares (Direct); Restricted Stock Unit — 0 shares (Direct)

Footnotes (1)

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jamil Khurram

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		M		60,000	A	$0(3)	60,000	D
Common Stock	01/02/2026		S(1)		13,055(1)	D	$4.1968(2)	46,945	D
Common stock	01/05/2026		S(1)		25,499(1)	D	$3.8985(5)	21,446	D
Common Stock	01/06/2026		S(1)		21,446(1)	D	$3.6466(6)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0(3)	01/01/2026		M			60,000(4)	01/02/2026(4)	(4)	Common Stock	60,000	$0	0	D

Explanation of Responses:

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

2. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

4. Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

5. The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

6. The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	Jack W. Callicutt, by power of attorney	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Galectin Therapeutics (GALT) report for Jamil Khurram?

The Chief Medical Officer, Jamil Khurram, reported vesting of 60,000 restricted stock units into common stock and subsequent sales totaling 60,000 shares of Galectin Therapeutics Inc common stock.

Were Jamil Khurrams Galectin Therapeutics share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Jamil Khurram on April 17, 2025, as previously disclosed in a Form 10-Q.

At what prices did the Galectin Therapeutics CMO sell GALT shares?

The filing reports weighted average sale prices of $4.1968 on January 2, 2026, $3.8985 on January 5, 2026, and $3.6466 on January 6, 2026, each representing multiple trades within disclosed price ranges.

How many Galectin Therapeutics shares did the CMO own after these transactions?

After the reported vesting and sales, the Form 4 shows 0 shares of Galectin Therapeutics Inc common stock beneficially owned by Jamil Khurram in the reported account.

What was the source of the 60,000 Galectin Therapeutics shares acquired by the CMO?

The 60,000 shares of common stock were acquired for no additional consideration upon vesting of restricted stock units, which were then converted into common shares on January 2, 2026.

Why are weighted average prices mentioned in the Galectin Therapeutics Form 4?

The filing explains that shares were sold in multiple transactions within price ranges, and the reported prices are weighted averages. The insider undertakes to provide details of each individual trade upon request.